In:
Therapeutic Advances in Respiratory Disease, SAGE Publications, Vol. 4, No. 2 ( 2010-04), p. 71-82
Abstract:
The management of asthma in children and adolescents is currently guided by assessment of clinical symptoms, exacerbation risk and spirometric measure of lung function. The use of biomarkers, an objective measure which indicates normal or pathophysiologic processes and/or the response to a treatment intervention, could greatly enhance the efficacy and safety of current algorithms. Measurement of the fraction of expired nitric oxide in exhaled air (FeNO) has been suggested as a readily determined biomarker that can aid in the diagnosis and management of asthma. FeNO has been used to identify steroid responsive patients, adjust the dose of controller medications, most notably inhaled corticosteroids, and predict relapse during medication taper. In spite of early enthusiasm for the utility of this measure, more recent data suggest a more limited role for FeNO. This review will focus on the use of FeNO in the diagnosis and management of asthma in children and adolescents.
Type of Medium:
Online Resource
ISSN:
1753-4666
,
1753-4666
DOI:
10.1177/1753465810361359
Language:
English
Publisher:
SAGE Publications
Publication Date:
2010
detail.hit.zdb_id:
2387506-9
Permalink
